A widely anticipated meeting with investors to discuss its R&D pipeline may not have the sort of impact that Sanofi had hoped. The drug maker attempted to make a splash this morning by touting predictions that 18 new products that may be introduced by 2020 could generate as much as $37 billion over the first five years of sales.. But there was some disappointing news folded into the projections.  The growth in the all-important diabetes business, which presently accounts for 21% of total revenue, is expected to be flat or show just slight improvements between 2015 and 2018.